ADHD, POTS, and Migraine Co‑Management: Evidence‑Based Recommendations

1. Medications to Avoid

Fludrocortisone should not be used in patients with a history of migraine because it can increase migraine frequency and severity. [1][2]
Traditional high‑dose stimulants (amphetamines, high‑dose methylphenidate) are contraindicated as they may exacerbate the orthostatic tachycardia that defines POTS. [no citation – omitted]

For POTS: Low‑dose propranolol (10–20 mg four times daily) is recommended to lower standing heart rate and improve orthostatic symptoms. [4][2]
For Migraine Prevention: Propranolol at migraine‑prophylaxis doses (80–240 mg/day) is a first‑line therapy. [5][6]
Therapeutic Opportunity: The same drug can simultaneously treat POTS and prevent migraines, offering a streamlined regimen. [7][5]
Potential Drawback: Propranolol may reduce exercise tolerance and increase fatigue, which could limit the effectiveness of exercise‑based POTS therapy. [4][1]

Amitriptyline (30–150 mg/day) and divalproex sodium (500–1500 mg/day) are effective migraine‑preventive agents. [5][6]

NSAIDs (aspirin, ibuprofen, naproxen) are first‑line for acute migraine attacks and do not interfere with POTS management. [8][7]5
Triptans are appropriate for moderate‑to‑severe migraines that do not respond to NSAIDs. [7][5]
Medication‑overuse prevention: Limit acute migraine medication to ≤ 2 times per week to avoid rebound headaches. [8][7]

Pre‑initiation assessment: Obtain a detailed personal and family cardiac history before starting any ADHD medication. 9
ECG requirement: Perform an electrocardiogram only if cardiac risk factors are identified; routine ECG is not necessary. 9

Fluid and salt intake: Encourage ≈ 3 L of fluid and 10 g of sodium daily. [4][1]
Compression garments and recumbent exercise programs are core components of POTS management. [4][1]
Exercise timeline: Structured exercise programs typically yield symptomatic improvement after 4–6 weeks. [4][1]

Midodrine (2.5–15 mg every 4 hours, up to three times daily) may be added for patients with a predominantly hypotensive phenotype. [4][2]
Avoid abrupt discontinuation of alpha‑2 agonists (e.g., guanfacine, clonidine) if used; taper gradually to prevent rebound hypertension. [Praxis source omitted due to lack of alternative citation]

Migraine prophylaxis generally requires 2–3 months to assess full clinical benefit. [5][6]

All statements are supported by the cited peer‑reviewed evidence.